CYP2D6 phenotyping in clinical practice: serum or urine dextromethorphan/dextrorphan metabolic ratio?
|Year of publication||2011|
|Type||Article in Proceedings|
|Conference||17th International Conference on Cytochrome P450|
|MU Faculty or unit|
|Field||Pharmacology and pharmaceutical chemistry|
|Description||The aim of this work was to elucidate if CYP2D6 phenotyping by evaluation of molar dextromethorphan to dextrorphan metabolic ratio (MRDEM/DOR) in serum has the usability and reliability as the assessment of MRDEM/DOR in urine. We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and investigated cut-off value for discrimination of poor metabolizers from extensive and intermediate ones. The correlation of serum MRDEM/DOR with urine MRDEM/DOR in 30 healthy volunteers was analysed in parallel.|